Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ferumoxtran-10

PreclinicalSmall molecule

MM.D. Anderson Cancer Center

ferumoxtran-10 is one of 2 small molecule programs targeting Nanoparticle. It is currently in Preclinical.

1

Indications

5

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

NanoparticleTerminated

NanoparticlePreclinical

Terminated

Competition

Competitive Landscape

2 competitors in Nanoparticle

#DrugCompanyPhaseTrials

Feraheme

SStanford University

ferumoxtran-10

MM.D. Anderson Cancer Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Nano MRI on 7 Tesla in Rectal and Breast Cancer

Unknown status·RRadboud University Medical Center·Phase 3·NCT02751606·30 enrolled

Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer

Completed·VVirginia Commonwealth University·Phase 2·NCT00107484·3 enrolled

Endometrial Cancer1 trial

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00416455·384 enrolled

Nanoparticle1 trial

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00147238·10 enrolled

Central Nervous System1 trial

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00659334·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ferumoxtran-10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ferumoxtran-10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ferumoxtran-10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MM.D. Anderson Cancer Center

Related News